The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Roughly half the world's population is already at risk of contracting the two diseases, which were once mainly confined to ...

Climate change is pushing disease-carrying tiger mosquitoes deeper into Europe, raising the risk that once-tropical viruses ...

A vaccine designed to protect against chikungunya, a mosquito-borne illness, has been temporarily paused for individuals aged 60 and older.

The FDA and CDC recommended a pause in administering Ixchiq, a chikungunya vaccine, in adults ages 60 and above after 17 serious adverse events, including two deaths.  About 80,000 Ixchiq doses have ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes ...

May 12 (UPI) --U.S. health officials are advising patients using the drug Ixchiq to hold off while authorities seek newer information on vaccine results in the global fight against chikungunya.